LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report)'s stock price traded up 5.5% during trading on Friday . The company traded as high as $43.30 and last traded at $43.98. 154,088 shares were traded during trading, a decline of 50% from the average session volume of 309,058 shares. The stock had previously closed at $41.69.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the company. Citigroup reiterated a "buy" rating and set a $49.00 price objective (up previously from $45.00) on shares of LENZ Therapeutics in a research report on Thursday, July 31st. Raymond James Financial increased their price objective on LENZ Therapeutics from $39.00 to $40.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Finally, HC Wainwright increased their price objective on LENZ Therapeutics from $38.00 to $48.00 and gave the company a "buy" rating in a research report on Monday, July 28th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $49.60.
Read Our Latest Analysis on LENZ Therapeutics
LENZ Therapeutics Stock Performance
The firm's 50 day simple moving average is $36.71 and its 200-day simple moving average is $30.51. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -22.25 and a beta of 0.45.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.58) by $0.05. The company had revenue of $5.00 million during the quarter, compared to analyst estimates of $5.00 million. As a group, equities analysts anticipate that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.
Institutional Investors Weigh In On LENZ Therapeutics
Large investors have recently bought and sold shares of the business. Paradigm Biocapital Advisors LP boosted its holdings in LENZ Therapeutics by 96.2% during the first quarter. Paradigm Biocapital Advisors LP now owns 1,511,932 shares of the company's stock valued at $38,872,000 after acquiring an additional 741,477 shares during the period. Vanguard Group Inc. boosted its holdings in LENZ Therapeutics by 1.8% during the first quarter. Vanguard Group Inc. now owns 1,199,462 shares of the company's stock valued at $30,838,000 after acquiring an additional 21,015 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in LENZ Therapeutics by 108.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 1,122,738 shares of the company's stock valued at $32,907,000 after acquiring an additional 585,000 shares during the period. Geode Capital Management LLC boosted its holdings in LENZ Therapeutics by 15.5% during the second quarter. Geode Capital Management LLC now owns 416,122 shares of the company's stock valued at $12,198,000 after acquiring an additional 55,730 shares during the period. Finally, Saturn V Capital Management LP bought a new stake in LENZ Therapeutics during the second quarter valued at about $10,033,000. 54.32% of the stock is currently owned by institutional investors.
LENZ Therapeutics Company Profile
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
See Also
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
